Uncategorized Archives - Page 8 of 163

TuesdayJun 16, 2026 10:00 am

How Authorities are Protecting Public Health During the FIFA World Cup

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada. An international sporting event of this magnitude presents a major challenge to public health planners, and authorities have been working fervently to put in place measures geared at keeping infectious disease risks at bay during the tournament. We discuss…

FridayJun 12, 2026 9:45 am

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation. Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value. Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive. Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting…

ThursdayJun 11, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”). VERAXA Biotech has successfully concluded a business combination…

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…

MondayJun 08, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company’s PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to improve…

FridayJun 05, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples. The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings. The global alcohol and drug testing devices market is…

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The…

WednesdayJun 03, 2026 9:45 am

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment. In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records. Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000. Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth. The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June. For many investors…

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

How Authorities are Protecting Public Health During the FIFA World Cup

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search